治疗使纤维化分期消退可降低HFE相关血色病患者的肝癌长期风险
该回顾性分析纳入法国或澳大利亚106例HFE C282Y纯合突变血色病患者,诊断时F3纤维化40例、F4纤维化66例,随访期间至少收集1次肝活检。末次活检时41例(38.6%)纤维化评分≤F2,其肝癌发生率显著低于末次活检仍为F3或F4者(4.8% vs 52.3%,P < .001)。多因素分析显示纤维化消退至≤F2与肝癌风险显著降低相关(HR,0.08;95% CI,0.01-0.62)。
要点
- 治疗可使HFE相关血色病患者的严重肝纤维化消退。
- 纤维化消退至≤F2者长期肝癌风险显著低于仍为F3或F4者。
- 男性、诊断年龄、糖尿病、过量饮酒及诊断时铁蛋白水平与肝癌风险相关。
核心结论
- 在HFE C282Y纯合突变血色病患者中,严重肝纤维化可随治疗消退。
- 纤维化消退至F2或以下者,长期肝癌风险显著降低。
研究设计与样本
- 回顾性分析法国或澳大利亚106例HFE C282Y纯合突变血色病患者,诊断时F3纤维化40例、F4纤维化66例。
- 随访期间至少收集1次肝活检,首次与末次肝活检中位间隔9.5年(范围3.5-15.6年)。
- 肝癌发生随访中位17.6年(范围9.8-24.1年)。
主要发现
- 末次肝活检时41例(38.6%)纤维化评分为F2或以下。
- 末次活检仍为F3或F4者肝癌发生34例(52.3%),末次活检≤F2者发生2例(4.8%),P < .001。
- 末次活检F3或F4者肝癌发生率为32.8/1000人年(95% CI,22.7-45.9/1000人年)。
- 末次活检≤F2者肝癌发生率为2.3/1000人年(95% CI,0.2-8.6/1000人年),P < .001。
- 多因素分析中,男性(HR,6.09;95% CI,1.21-30.4)、诊断时年龄(HR,1.16;95% CI,1.09-1.25)、糖尿病(HR,3.07;95% CI,1.35-6.97)、过量饮酒(HR,3.1;95% CI,1.47-6.35)、诊断时铁蛋白水平(P < .01)及纤维化消退至≤F2(HR,0.08;95% CI,0.01-0.62)与肝癌风险显著相关。
临床怎么用
- 对HFE相关血色病患者应积极治疗并随访肝纤维化分期。
- 纤维化消退至F2或以下提示长期肝癌风险显著降低,但仍需结合其他危险因素评估。
局限性
- 本研究为回顾性分析,样本量106例,可能存在选择偏倚与混杂。
- 肝活检间隔与随访时间范围较宽,纤维化评估可能受采样误差影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fibrosis stage can decrease following treatment in patients with hemochromatosis caused by mutations in the homeostatic iron regulator gene (HFE), but the effects on cirrhosis are not clear. We assessed regression of severe fibrosis and the ensuing risk of liver cancer after treatment. METHODS: We performed a retrospective analysis of data from 106 patients in France or Australia who were homozygous for the C282Y mutation in HFE with F3 fibrosis (n = 40) or F4 fibrosis (n = 66) at diagnosis and from whom at least 1 liver biopsy was collected during follow up. We collected data from the time of first biopsy and during follow-up period on patient demographics, treatment, smoking habits, alcohol consumption, infection with hepatitis B or C viruses, and other diseases. The median time between first and last liver biopsy was 9.5 years (range, 3.5-15.6 years). We collected results of tests for liver function, markers of iron stores, and platelet levels. Patients were followed for a median 17.6 years (range, 9.8-24.1 years) for development of liver cancer occurrence. RESULTS: At last liver biopsy, 41 patients (38.6%) had fibrosis scores of F2 or less. Liver cancer occurred in 34 patients (52.3%) with F3 or F4 fibrosis at last liver biopsy vs 2 patients (4.8%) with fibrosis scores of F2 or less at last liver biopsy (P < .001). Liver cancer incidences were 32.8 per 1000 person-years (95% CI, 22.7-45.9 per 1000 person-years) in patients with F3 or F4 fibrosis and 2.3 per 1000 person-years (95% CI, 0.2-8.6 per 1000 person-years) in patients with fibrosis scores of F2 or less (P < .001). In multivariate analysis, male sex (hazard ratio [HR], 6.09; 95% CI, 1.21-30.4), age at diagnosis (HR, 1.16; 95% CI, 1.09-1.25), presence of diabetes (HR, 3.07; 95% CI, 1.35-6.97), excess alcohol consumption (HR, 3.1; 95% CI, 1.47-6.35), serum level of ferritin at diagnosis (P < .01), and regression to fibrosis scores of F2 or less (HR, 0.08; 95% CI, 0.01-0.62) were significantly associated with risk of liver cancer. CONCLUSIONS: In a retrospective analysis of patients with hemochromatosis caused by the C282Y mutation in HFE, we found that severe liver fibrosis can regress with treatment. In patients with fibrosis regression to a stage F2 or less, the long-term risk for liver cancer is significantly reduced.
引用
- Bardou-Jacquet E, Morandeau E, Anderson GJ, et al. Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE. Clin Gastroenterol Hepatol. 2019. PMID: 31622736. doi:10.1016/j.cgh.2019.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。